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Abstract
Background: Control of methicillin-resistant Staphylococcus aureus (MRSA) transmission has been unsuccessful in
many hospitals. Recommended control measures include isolation of colonized patients, rather than decolonization
of carriage among patients and/or health care workers. Yet, the potential effects of such measures are poorly
understood.
Methods: We use a stochastic simulation model in which health care workers can transmit MRSA through
short-lived hand contamination, or through persistent colonization. Hand hygiene interrupts the first mode,
decolonization strategies the latter. We quantified the effectiveness of decolonization of patients and health care
workers, relative to patient isolation in settings where MRSA carriage is endemic (rather than sporadic outbreaks in
non-endemic settings caused by health care workers).
Results: Patient decolonization is the most effective intervention and outperforms patient isolation, even with low
decolonization efficacy and when decolonization is not achieved immediately. The potential role of persistently
colonized health care workers in MRSA transmission depends on the proportion of persistently colonized health
care workers and the likelihood per colonized health care worker to transmit. As stand-alone intervention, universal
screening and decolonization of persistently colonized health care workers is generally the least effective
intervention, especially in high endemicity settings. When added to patient isolation, such a strategy would have
maximum benefits if few health care workers cause a large proportion of the acquisitions.
Conclusions: In high-endemicity settings regular screening of health care workers followed by decolonization of
MRSA-carriers is unlikely to reduce nosocomial spread of MRSA unless there are few persistently colonized health
care workers who are responsible for a large fraction of the MRSA acquisitions by patients. In contrast,
decolonization of patients can be very effective.
Background
Methicillin resistant Staphylococcus aureus (MRSA) is an
important cause of nosocomial infections. The dynamics
of MRSA transmission in health-care settings is character-
ized by high fluctuations in patient prevalence within
units, resulting from patient-to-patient spread and admis-
sions of colonized patients. So far, almost all interventions
have been based on implementing barrier precautions for
patients with documented MRSA carriage [1,2], some-
times in combination with decolonization of carriage [3].
The evidence for the efficacy of patient isolation to control
nosocomial spread of MRSA in high endemicity settings,
though, is rather limited [4].
Especially for MRSA, health care workers (HCWs)
might be important in the nosocomial transmission dy-
namics. First, temporary contaminated hands of HCWs
are important vectors for MRSA transmission [5], and
appropriate hand hygiene is considered the key interven-
tion to minimize this transmission mode [6]. Second,
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HCWs may become persistently colonized with MRSA
[7], e.g., in the nose or on injured skin, and act as a con-
stant source for MRSA transmission [7]. The obvious
difference between both transmission roles is that hand
hygiene will not clear persistent carriage.
MRSA eradication therapies using mupirocin and
chlorhexidine were extremely efficacious in decolonizing
HCWs [8]. If persistent carriage among HCW is an im-
portant source for MRSA transmission, decolonization
of HCWs could be effective in controlling MRSA among
patients. To the best of our knowledge, though, the rela-
tive contribution of persistently colonized HCWs in the
epidemiology of MRSA endemicity has never been deter-
mined, and, consequently, there is no information on
the possible effects of decolonizing persistently colo-
nized HCWs. In contrast the efficacy of eradication ther-
apies applied to patients during hospitalization seems to
be low [8]. Clinical decision making for the most appro-
priate infection control strategy is frequently hampered
by the absence of prospective comparisons of different
control strategies. Moreover, even if performed, the im-
portance of stochastic events in small populations, such
as in hospitals, would necessitate long periods of follow-
up. In the absence of empirical evidence, mathematical
models may offer the best alternative to determine the
optimal control strategy [9].
Here, we use a computer simulation model to quantify
the effects of patient isolation and antimicrobial treat-
ment of carriage for patients and HCWs, as part of an
infection control program for MRSA with universal hos-
pital admission screening. We aim to identify scenarios
in which HCW decolonization could be considered a
sensible intervention.
Methods
Patient and transmission dynamics
We use an extended version of a previously described
stochastic simulation model [10]. The model contains
three hospitals of 693 beds, each with an extramural
population of 220,000 subjects. Patients are subdivided
into “core group” and “non core group” patients, distin-
guished by hospitalization rates of once per year (core-
group) and once per ten years (non-core group). On
average 50% of the hospital population consists of “core
group” patients.
Each hospital comprises two types of wards: five 9-bed
Intensive Care Units (ICUs) and 36 18-bed regular
wards. In ICUs the staff-patient ratio is 9:9, in regular
wards 5:18. Besides HCWs confined to a single ward, 80
HCWs are present who have contact with patients in
different wards. HCWs work in 8-hours shifts. HCWs
confined to a single ward will work in the same ward
during their next shift. Upon hospitalization patients can
be admitted to both types of wards. In ICUs, 70% of the
patients stay, on average, 1.5 days, with an ICU mortality
of 2%. After ICU discharge, these patients stay, on aver-
age, seven days in regular wards, before hospital dis-
charge. The remaining 30% of ICU-patients stay, on
average, 10 days in ICU and have an ICU-mortality of
25%. ICU survivors remain hospitalized for, on average,
15 days in regular wards. These figures are based on real
patient data from a multi-center ICU study in the Neth-
erlands [11]. Length of stay is assumed to be independ-
ent of the colonization status. Apart from transfer from
ICUs to wards, patients can be transferred between
regular wards, from regular wards to ICUs, between
ICUs, and between hospitals, all with different rates. Im-
portant parameters used are listed in Table 1.
Patients are either carriers of MRSA or uncolonized
and susceptible for colonization. Infection control inter-
ventions, however, are not based on the true
colonization status, but on the available documentation
of the colonization status only.
On hospital admission, MRSA carriage can be docu-
mented with a rapid diagnostic test that, for simplicity,
provides a result in 24hours with sensitivity and specifi-
city of 93% and 96% respectively [12]. Simultaneously,
conventional microbiological tests, with assumed sensi-
tivity and specificity of 100% and turn-around time of
Table 1 Parameters in the model
Parameter Value Source
Average length of stay in intensive
care units
4 days [17]
Average length of stay in regular
ward
7 days UMC
Admission from another hospitals 5% UMC
Staff : patient ratio in intensive
care units
1:1 UMC
Staff : patient ratio in regular ward 5:18 UMC
Staff : patient ratio of HCWs not
restricted to single wards
~1:8.7 UMC
Duration of colonization in
extramural population (mean)
370 days [13,14]
Transmission risk intensive care units :
regular ward
3:1 Assumption
Specificity of rapid diagnostic test 96% [12]
Sensitivity of rapid diagnostic test 93% [12]













Turnaround time of conventional
microbiological test (back-up test)
4 days [12]
UMC-parameters estimated from data from University Medical Center Utrecht.
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four days, are performed as back-up to adjust false test
results of rapid tests. All patients should be screened on
admission (i.e., universal screening), and we assume that
compliance to this screening scenario is 88% (based on
UMCU data) [10]. MRSA carriage may also be detected
by clinical cultures, which are processed with conven-
tional microbiological methods.
Patients can acquire MRSA by two modes: The first
mode occurs via the hands of HCWs, which may have
become contaminated after contact with a colonized pa-
tient. Appropriate hand hygiene will clean hand contam-
ination and, therefore, hand contamination is typically
short-lived. As a consequence, the probability of trans-
mission via hands of temporary colonized HCWs is pro-
portional to the fraction of colonized patients in the
unit. The second acquisition mode is through persist-
ently colonized HCWs, e.g., with carriage in the nares.
This type of colonization is not short-lived and is not
eradicated through hand hygiene. We assume that the
risk for HCWs to become persistently colonized is pro-
portional to the number of patients being colonized.
HCWs and patients may lose MRSA carriage in the
extramural community after a median time of 256 days
(mean of 370 days) [13,14]. Importantly, there is no
patient-to-patient transfer of MRSA in the community,
which limits our analyses to so-called hospital-acquired
MRSA.
Most analyses are performed in settings with high en-
demicity levels of MRSA, i.e., in absence of any interven-
tion specifically targeted at MRSA, the equilibrium
patient prevalence of MRSA-carriage is around 14% and
40% in hospitals and ICUs, respectively. A medium en-
demicity level of around 6% and 20% in hospitals and
ICUs, respectively, was analysed as well. A medium en-
demicity level is most realistic [15]. However, an MRSA-
prevalence of 20% is not uncommon [16]. Transmission
parameters in regular wards and ICUs were chosen to
obtain these patient prevalences of MRSA and to obtain
a prevalence of persistently colonized HCWs of 1%, 5%
or 10%, while 10%, 30% or 50% of the acquisitions in
patients can be ascribed to persistently colonized HCWs
(see Additional file 1). As the feedback loop, (i.e. colo-
nized patients who are discharged and readmitted) is
included in our model we obtain the MRSA admission
prevalence as a result of the chosen transmission
parameters.
Note that we do not specify 1) hand hygiene compli-
ance levels, 2) cohorting levels, 3) environmental clean-
ing protocols, 4) the use of single/multi bed rooms,
5) the frequency of contact between patients and HCW,
and other factors influencing MRSA transmission. The
effectiveness of interventions depends on the prevalence
and relative importance of transmission modes only, and
not directly on the aforementioned parameters. For
instance, a high hand hygiene compliance with a low
cohorting level will have the same effect on transmission
as a low compliance with a high cohorting level. On top
of the dynamics of MRSA as described in this section,
we model intervention strategies, as described below, to
address our research questions.
Interventions
We consider two control strategies applied to patients
with documented MRSA-carriage, and one applied to
HCWs:
a) Isolation reduces both the likelihood for colonized
patients to transmit MRSA and the likelihood for
uncolonized patients (when isolated) to acquire
colonization. The efficacy of isolation ranges from 0%
(no effect of isolation) to 100% and is modelled as a
multiplication factor (0 to 1) to transmission rates.
Isolation with suboptimal efficacy could be
considered to resemble strategies in which patients
are not isolated in single-bed rooms, but in which
other barrier precautions, e.g., gloves and gowns, are
used instead. The number of beds available for
patient isolation is unlimited, which allows
quantification of the isolation needs for each
intervention. Isolation measures are initiated when
MRSA carriage (or infection) is documented.
Isolation will be discontinued when screening
cultures do not yield MRSA.
b)Decolonization of patients occurs a fixed number of
days after the start of decolonization therapy. Until
that time, or if decolonization is unsuccessful, the
infectivity of a treated individual remains unaffected.
If patients are discharged before the treatment is
completed, the treatment will be continued
extramurally. The efficacy of decolonization is
denoted as the percentage of patients in which
decolonization is successful. Decolonization is
initiated on the same day that MRSA-carriage is
documented. A successfully decolonized patient is
immediately susceptible for acquisition of MRSA. If
not specified otherwise, decolonization occurs
instantaneously.
c) Decolonization of HCWs is assumed to be 100%
efficacious and occurs, for simplicity, instantaneously.
We explore the effects of decolonizing all staff with
frequencies ranging from monthly to annually. After
decolonization, HCWs are immediately susceptible
for acquisition of MRSA.
Simulations for which we report 95% credibility inter-
vals are always based on 1000 1,000 independent runs of
the stochastic simulation model. Mean values can be
based on 50 independent runs. We define the effectiveness
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of an intervention a time after the intervention has been
implemented as the mean relative reduction in the
hospital-wide MRSA prevalence.
Results
Comparing patient isolation and decolonization
With similar levels of efficacy, decolonization is more ef-
fective than patient isolation (Figure 1). Decolonized
patients cannot reintroduce MRSA when readmitted to
the hospital, which interrupts the so-called feedback
loop. Another benefit of decolonization is that the noso-
comial patient prevalence of MRSA decreases faster as
compared to isolation strategies, because decolonization
decreases the number of colonized patients in the hos-
pital directly while isolation only prevents new acquisi-
tions while patients in isolation are still colonized
Nosocomial MRSA patient prevalence will decrease
slower with a lower efficacy of control measures. With a
lower efficacy of decolonization and isolation, the differ-
ence in patient prevalence between both interventions
decreases during the first months after implementation.
Three months after the start of interventions, the abso-
lute difference in nosocomial MRSA patient prevalence
between decolonization and isolation is 3.9% with 100%
efficacy and 3.7%, 3.1% and 1.7% with 75%, 50% and 25%
efficacy, respectively with a high endemicity level
(14% hospital-wide) and 2.2%, 2.0%, 1.6% and 1.1% with
an efficacy of isolation of 100%, 75%, 50% and 25% with
a medium endemicity level (6% hospital-wide). On
longer time scales, though, differences in patient preva-
lence between interventions show opposite trends. After
5 years the difference is 0.7% with 100% efficacy, and
1%, 2.9% and 4.5% with 75%, 50% and 25% efficacy,
respectively. With a medium patient prevalence endem-
icity level, the difference is 0.7% with 100% efficacy, and
1.2%, 1.6% and 1.6% with 75%, 50% and 25% efficacy, re-
spectively (see Figure 1).
Using an arbitrary goal for the ultimate patient preva-
lence of 0.3%, this goal will be reached in 5 years if the
efficacy of patient decolonization exceeds 75% (Figure 1).
For isolation, the patient prevalence will decrease slower.
Even with a 100% efficacy the patient prevalence will be
1.5% after five years and the patient prevalence will be
2.3% and 5.8% with 75% and 50% efficacy respectively.
The effect of non-instantaneous decolonization of
patients and HCWs is discussed in the Additional file 1.
Role of health care workers
The role of persistently colonized HCWs is composed of
two aspects: the percentage of HCWs being persistently
colonized (which depends on the probability for a non-
colonized HCW to acquire colonization from a colo-
nized patient) and the likelihood per colonized HCW to
act as a source. Due to these different aspects few highly
infectious persistently colonized HCWs may spread
MRSA to the same number of patients as many persist-
ently colonized HCWs who are individually less prone
to spread MRSA. The benefits of decolonizing HCWs
importantly depend on these parameters. Of note, this
does not include their role as vectors with temporarily
contaminated hands, which was considered as patient-
to-patient transmission. We have evaluated the dynamics
of the MRSA patient prevalence for several values of
both aspects. The proportion of HCWs being persist-
ently colonized ranged from 1% to 10%, and proportions
of patient acquisitions resulting from persistently colo-
nized HCW ranged from 10% to 50%. We quantified the
effects of monthly, biannually and yearly decolonization
of HCWs (Figure 2 and Additional file 1: Figure S1).
The largest benefit from HCW decolonization is
achieved when few persistently colonized HCWs are re-
sponsible for a large proportion of acquisitions. Natur-
ally, monthly decolonization of HCWs is more effective
than biannual and annual decolonization, but always less
effective than decolonization of patients with documen-
ted MRSA carriage with an efficacy of 100%.
In practice, though, decolonization of patients will be
less often successful than decolonization of HCWs [8].












































Figure 1 Patient prevalence level of MRSA as function of the efficacy of patient decolonization or isolation after 3 months, 1 year and
5 years. 88% of the patients are screened upon hospital admission. Carriers are either decolonized (red lines) or isolated (blue lines). The left
figure corresponds to a high endemicity level, the right figure to a medium endemicity level.
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We have, therefore, determined how efficacious patient
decolonization should be to achieve the same MRSA pa-
tient prevalence (in 15 years after the start of the inter-
vention) as 100% efficacious HCW decolonization
(Additional file 1: Table S1 in the additional file). The
maximum efficacy needed is 55%-68% for scenarios in
which 50% of acquisitions result from persistently colo-
nized HCWs. Yet, when persistently colonized HCWs
are responsible for 10% of all acquisitions, efficacy of pa-
tient decolonization need only be 8%-9%. With a
medium endemic prevalence, it will take more time be-
fore HCWs become persistently colonized. Therefore,
interventions targeted at HCWs become more effective
in settings with a lower patient prevalence (data not
shown).
As HCW decolonization has been used in combination
with patient isolation in several countries, we also inves-
tigated the effects of perfect periodical decolonization of
HCWs in combination with patient isolation (with 50%
efficacy). In Figure 3 we have depicted the most extreme
scenarios (i.e., 10% prevalence among HCWs being re-
sponsible for 10% of acquisitions, and 1% of HCWs
being responsible for 50% of acquisitions) in settings
with higher endemicity level . As expected, the add-
itional benefit of HCW decolonization is much higher in
the latter scenario (Figure 3) but differences between
decolonization frequencies are relatively small. The ef-
fect of the combined intervention in settings with
medium endemicity level is shown in the additional file
(Additional file 1: Figure S2).
The additional benefit of HCW decolonization is also
influenced by the efficacy of patient isolation. Again
using the two extremes as illustration, the benefit of
adding HCW decolonization is much less sensitive to
the efficacy of patient isolation when few HCWs are re-
sponsible for many acquisitions (Figure 4 for settings
with a high endemicity level and Additional file 1: Figure
S3 for a medium endemicity level).
In real life, multiple interventions are usually applied
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Figure 2 The effects of health care worker decolonization on the patient prevalence level of MRSA. Scenarios I and II, correspond to the
relative importance of persistently colonized health care workers (HCW) in the spread of MRSA (being 50% and 10 %, respectively) in the
endemic situation. Scenarios A and B correspond to different values for the percentage of persistently colonized HCWs. Results are based on 50
runs of the stochastic simulation model. The lines represent the average hospital-wide MRSA patient prevalence, starting from the baseline
scenario of an average patient prevalence of 14% (high endemicity level). The red line represents the patient prevalence with patient
decolonization (100% efficacious ) and the other lines represent the patient prevalence with health care worker decolonization (100% efficacious)
performed once per year (blue), twice per year (purple) and every month (yellow).
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incremental effect of HCW decolonization to patient
isolation and decolonization together. When isolation
efficacy of patients with MRSA is 50% and de-
colonization efficacy among patients would be 90%, add-
itional effects of HCW decolonization will be small, even
for the `best-case scenario` of monthly decolonization
with 1% of HCW being persistently colonized and
responsible for 50% of acquisitions (data not shown).
When the efficacy of patient decolonization is only 10%
and isolation efficacy is 50%, monthly decolonization of
HCWs will only substantially reduce MRSA patient
prevalence in the extreme scenario with 1% of the HCW
being persistently colonized and responsible for 50% of
the acquisitions.
A










































Patient isol. eff. 50%
Patient isol. eff. 50% + HCW decol. 1/year
Patient isol. eff. 50% + HCW decol. 2/year
Patient isol. eff. 50% + HCW decol. 6/year
patients decol. eff.100%
Figure 3 Effect of combining patient isolation with decolonization of health care workers. The two graphs correspond to scenarios with
minimum effect of decolonization of HCWs (A) (10% of HCWs are persistently colonized and responsible for 10% of acquisitions ) and maximum
(B) (1% of HCWs is persistently colonized and responsible for 50% of acquisitions). The effect of patient decolonization (100% efficacious) is added
for comparison.
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Isol. eff. 50%, no HCW decol.
Isol. eff. 25%, HCW decol. 2/year
Isol. eff. 50%, HCW decol. 2/year
Isol. eff. 75%, HCW decol. 2/year
Decol. eff.100%, no HCW decol.
Figure 4 Effect of the patient isolation efficacy when combined with biannual decolonization of health care workers. The two graphs
correspond to scenarios with minimum effect of decolonization of HCWs (A) (10% of the HCWs are persistently colonized and responsible for
10% of acquisitions) and maximum (B) (1% of the HCWs is persistently colonized and responsible for 50% of acquisitions). The efficacy of HCW
decolonization is 100%. Lines with patient decolonization (100% efficacious) and only isolation (50% efficacious) are added for comparison.
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Discussion
We have used a mathematical model to investigate the
effects of isolation strategies for patients and of
decolonization for patients and HCWs. Our findings
demonstrate that – with similar levels of efficacy -
patient decolonization is more effective than patient
isolation and that active decolonization of persistently
colonized HCWs only has a significant impact if a con-
siderable proportion (e.g., 50% or more) of the MRSA
acquisitions by patients can be ascribed to persistently
colonized HCWs.
Our analyses clearly illustrate the two processes that
determine the potential role of persistently colonized
HCWs in MRSA transmission. One of these parameters,
the proportion of HCWs being colonized, can easily be
determined. Reported point-prevalence rates of HCW
colonization in the nares range from <0.1% in Dutch
hospitals with low endemic levels of MRSA [17] to
5-6% in hospitals with high endemic levels [18-21]. The
other parameter, though, the relative contribution of
these colonized HCWs for MRSA acquisition, is much
more difficult to quantify, as both extensive screening
among patients and HCWs and genotyping to demon-
strate genetic similarities of MRSA isolates would be
needed. Despite multiple, usually anecdotal, reports
about MRSA carriage in HCWs, (as reviewed in [7]),
this parameter has to the best of our knowledge never
been quantified.
Naturally, the relative effects of HCW decolonization
depend on the parameters used in the model. For in-
stance, at lower endemic levels of MRSA the effects of
HCW decolonization would be relatively higher. How-
ever, the dependency of two parameters, the fraction
persistently colonized HCWs and the percentage of
acquisitions resulting from them, remains important in
all settings and estimation of these parameters in clinical
settings will allow more precise determination of the ef-
fectiveness of HCW decolonization in reducing nosoco-
mial MRSA-transmission.
Several studies have attempted to quantify the effects of
bacterial eradication therapies in hospitalized patients
[22,23]. In a systematic review, nasal application of mupir-
ocin had, as compared to placebo, an estimated pooled
relative risk of failure to eradicate nasal S. aureus carriage
after one week of 0.10 (0.07-0.14), and effects were similar
for patients and healthy subjects as well as in studies in-
cluding only MSSA or both MSSA and MRSA carriers [8].
In a recent study, a combined approach of universal
screening of MRSA carriage with PCR testing, followed by
topical decolonization with mupirocin and isolation pre-
cautions for carriers, was associated with a 69.6% reduc-
tion in the aggregate hospital-associated MRSA disease
incidence [24]. However, in the latter study, as in most
studies in the systematic review, several interventions
were tested simultaneously, hampering accurate quantifi-
cation of the effects of decolonization.
In a Spanish intensive care burn unit topical applica-
tion of vancomycin in the nose, oropharynx and intes-
tines was evaluated in an observational before-after
study during nine years [25]. Although no data are pre-
sented about the decolonization efficacy on a patient
level, acquisition rates and average endemic patient
prevalence levels were 80% lower with vancomycin use.
Another option, which we did not investigate, would
be to restrict HCW decolonization to outbreak settings
only. This strategy could lower the decolonization fre-
quency of HCWs, especially when outbreaks are rare.
However, the effectiveness of this strategy strongly
depends on the definition of an outbreak and the sensi-
tivity of detecting outbreaks.
Our analysis of non-instantaneous decolonization in
the Additional file 1 is limited to patients. Indeed, in-
stantaneous decolonization of HCWs may always be
achieved in practice by temporary dismissal of known
colonized HCWs and by replacing those by uncolonized
ones.”
Although decolonization of patients seems, at least
theoretically, an effective measure, these benefits should
be balanced with potential adverse events. Topical use of
mupirocin and antibiotics are considered safe, but selec-
tion of antibiotic resistance remains a potential threat.
Especially the use of topical vancomycin should be care-
fully judged, as vancomycin is one the few remaining
antibiotics available for intravenous treatment of MRSA
infections.
Naturally, the model used is a simplification of reality.
For instance, there are many specialized hospital wards
with different patient populations and different patient
transfer rates to other wards. Also, the susceptibility of
patients to acquire MRSA will differ. Furthermore, we
assumed that length of stay was not affected by
colonization status, that all HCWs work in shifts of 8 hour,
that direct transmission of MRSA between HCWs did not
occur and that HCWs could not acquire persistent
colonization outside hospital settings, e.g. from their colo-
nized homes or families. Also, isolation was assumed to be
equally efficacious in all isolated patients, which may not
be true if the number of isolation beds available is limited.
Finally, we did not explicitly model resistance develop-
ment as a result of decolonization strategies. Our findings
should, therefore, not be interpreted as a definitive argu-
ment in favour of widespread use of antibiotics for con-
trolling the nosocomial spread of MRSA, but more as an
illustration that different approaches might be more ef-
fective than our current strategies. Furthermore, we have
identified research targets that could be pursued in epi-
demiological studies that are needed to further quantify
the potential benefits of HCW decolonization.
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Conclusions
Based upon a theoretical framework, we have identified
the scenarios in which decolonization of persistently
colonized HCWs, either as a stand-alone measure or
when added to interventions targeted at colonized
patients, can significantly improve MRSA control in
health care settings. In general, decolonizing HCWs
becomes more beneficial when their carriage rates de-
crease and – simultaneously – their contribution to pa-
tient acquisition (per colonized HCW) increases.
Yet, decolonization of MRSA carriage among patients
will be more efficacious than decolonization of HCWs in
most scenarios with high endemicity levels, even for a
low decolonization efficacy among patients. Further-
more, patient isolation, albeit conceptually less efficient
than patient decolonization, will also be more effective
than HCW decolonization. Note that if decolonization
therapy in patients would not eradicate MRSA carriage,
but only suppresses infectiousness by lowering the bac-
terial load, decolonization is conceptually similar to pa-
tient isolation as both reduce infectiousness without
interrupting the feedback loop of colonized patients
being readmitted. Considering the continuously rising
patient prevalence levels of MRSA and the repeatedly
reported failures of isolation policies to control its
spread, our findings support further evaluation of
pharmacological (and other) strategies to actively achieve
eradication of MRSA carriage in patients.
Additional file
Additional file 1: Figure S1. The effects of health care worker
decolonization on the patient prevalence level of MRSA. Figure S2. The
effects of combining patient isolation with 100% efficacious
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